This study is currently not recruiting participants.
Validation of the Clinical Performance of HemosIL CL Anti-Cardiolipin IgG & IgM assays HemosIL CL Anti-B2 Glycoprotein-I IgG & IgM assays and HemosIL Multi-Ab Controls-Performance Evaluation Matrix Comparison on the SCL TOP 970 CL Matrix Comparison: Fresh vs Frozen
Not Recruiting
100 years or below
All
Phase
N/A
1 Location
Brief description of study.
The purpose of this study is to demonstrate there is no statistically significant difference in the result of plasma samples when analyzed fresh and the results afrer one (1) and two (2) freeze/thaw cycles on the ACL TOP 970 CL analyzer with the following assays:
HemosIL CL Anit-Cardiolipin IgG
HemosIL CL Anti-Cardiolipin IgM
HemosIL CL Anti-B2 Glycoproteitin-I IgG
HemosIL CL Anti-B2 Glycoprotein-I IgM
Detailed description of study
The purpose of this study is to demonstrate there is no statistically significant difference in the result of plasma samples when analyzed fresh and the results afrer one (1) and two (2) freeze/thaw cycles on the ACL TOP 970 CL analyzer with the following assays:
HemosIL CL Anit-Cardiolipin IgG
HemosIL CL Anti-Cardiolipin IgM
HemosIL CL Anti-B2 Glycoproteitin-I IgG
HemosIL CL Anti-B2 Glycoprotein-I IgM
Eligibility of study
You may be eligible for this study if you meet the following criteria:
Conditions:
Age:
100 years or below
Gender: All
Updated on
07 Nov 2018.
Study ID: 1809615095
Interested in the study?
Select a study center that’s convenient for you, and get in touch with the study team.
